Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dalcetrapib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP known ✓ | P11597 | 18/20 | 1.00 |
| ▸ | MDM4 | O15151 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dalcetrapib SCHEMBL29350009 | 1.00 | CETP (1.00) | CETPMDM4TP53MDM2 | |
| SCHEMBL2679960 | 0.93 | CETP (0.86) | CETPMDM4TP53MDM2 | |
| SCHEMBL529033 | 0.90 | CETP (0.82) | CETPMDM4TP53MDM2 | |
| SCHEMBL528587 | 0.89 | CETP (1.00) | CETP | |
| SCHEMBL23976782 | 0.88 | CETP (0.82) | CETP | |
| SCHEMBL16844336 | 0.88 | CETP (0.82) | CETP | |
| SCHEMBL2486998 | 0.88 | CETP (0.78) | CETPMDM4TP53MDM2 | |
| SCHEMBL29352194 | 0.88 | CETP (0.81) | CETP | |
| SCHEMBL529503 | 0.88 | CETP (0.81) | CETP | |
| SCHEMBL2705151 | 0.88 | CETP (0.81) | CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1753 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026087680-A1 | TREATMENT FOR CARDIOVASCULAR DISEASE | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| US-12485157-B2 | Method of treating COVID-19 | PFIZER INC. (US) | 2025-12-02 | — | — | US | claimed |
| US-12371748-B2 | Genetic markers for predicting responsiveness to therapy with HDL-raising or HDL mimicking agent | HOFFMANN-LA ROCHE INC. (US) | 2025-07-29 | — | — | US | claimed |
| US-20250191770-A1 | COMPUTERIZED DECISION SUPPORT TOOL AND MEDICAL DEVICE FOR RESPIRATORY CONDITION MONITORING AND CARE | PFIZER INC. (US) | 2025-06-12 | — | — | US | claimed |
| US-12150975-B2 | Therapeutic combinations to treat red blood cell disorders | HARTIS-PHARMA SA (CH) | 2024-11-26 | — | — | US | claimed |
| WO-2024189434-A1 | USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2 | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2024-09-19 | — | — | WO | claimed |
| US-20240148913-A1 | LIPOSOMAL NANOCARRIER DELIVERY SYSTEM FOR TARGETING ACTIVE CD44 MOLECULE,PREPARATION METHOD THEREFOR, AND USES THEREOF | BEIJING INNO MEDICINE CO., LTD. (CN) | 2024-05-09 | — | — | US | claimed |
| CN-111073974-B | Genetic markers for predicting responsiveness to treatment | 豪夫迈·罗氏有限公司 | 2024-04-09 | — | — | CN | claimed |
| EP-4304717-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | Chronic Airway Therapeutics Limited (AU) | 2024-01-17 | — | — | EP | claimed |
| CN-117138047-A | Application of TLR4 inhibitor in preparation of medicine for relieving gastrointestinal toxicity caused by sorafenib | 中山大学 | 2023-12-01 | — | — | CN | claimed |
| US-20050020668-A1 | Combination comprising S-[2-([[1-(2-ethylbutyl)cyclohexyl] carbonyl]amino)phenyl] 2-methylpropanethioate and an HMG CoA reductase inhibitor | JAPAN TOBACCO INC. (JP) | 2005-01-27 | — | — | US | claimed |
| US-20040242683-A1 | Method for increasing the bioavailability of the active form of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl] amino)phenyl] 2-methylpropanethioate | JAPAN TOBACCO INC. (JP) | 2004-12-02 | — | — | US | claimed |
| US-20040229957-A1 | cholesterol ester transfer protein inhibitors, new type of a preventive or therapeutic agent for atherosclerosis or hyperlipidemia | JAPAN TOBACCO INC. (JP) | 2004-11-18 | — | — | US | claimed |
| WO-2004098583-A1 | COMBINATION COMPRISING S-[2-([[1-(2-ETHYLBUTYL)CYCLOHEXYL]CARBONYL]AMINO)PHENYL]2-METHYLPROPANETHIOATE AND AN HMG COA REDUCTASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2004-11-18 | — | — | WO | claimed |
| US-20040225018-A1 | administering S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl] 2-methylpropanethioate and a water-insoluble concentration-enhancing additive crospovidone, for treating or preventing a cardiovascular disorder in a mammal | JAPAN TOBACCO INC. (JP) | 2004-11-11 | — | — | US | claimed |
| WO-2004082675-A1 | METHOD FOR INCREASING THE ORAL BIOAVAILABILITY OF S-[2- ([[1- (2-ETHYLBUTYL) CYCLOHEXYL] CARBONYL] AMINO) PHENYL] 2-METHYLPROPANETHIOATE | JAPAN TOBACCO INC. (JP) | 2004-09-30 | — | — | WO | claimed |
| WO-2004082593-A2 | PHARMACEUTICAL COMPOSITIONS OF CETP INHIBITORS | JAPAN TOBACCO INC. (JP) | 2004-09-30 | — | — | WO | claimed |
| US-20030092708-A1 | Anticholesterol agents; cardiovascular disorders; antilipemic agents | JAPAN TOBACCO, INC., A JAPAN CORPORATION | 2003-05-15 | — | — | US | claimed |
| US-6426365-B1 | Anticholesterol agents; Cholesterol ester transfer protein (CETP); including dalcetrapib, S-(2-(((1-(2-ethylbutyl)cyclohexyl)carbonyl)amino) phenyl) 2-methylpropanethioate | JAPAN TOBACCO INC. (JP) | 2002-07-30 | — | — | US | claimed |
| EP-1020439-A1 | CETP ACTIVITY INHIBITORS | JAPAN TOBACCO INC. (JP) | 2000-07-19 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229957-A1 | cholesterol ester transfer protein inhibitors, new type of a preventive or therapeutic agent for atherosclerosis or hyperlipidemia | CETP, MTTP, LCAT | CETP 1/4885MDM4 4594/4885TP53 4550/4885 |
| US-12485157-B2 | Method of treating COVID-19 | ACE2, ACE, TMPRSS2 | CETP 172/4885MDM4 1179/4885TP53 1168/4885 |
| US-20030092708-A1 | Anticholesterol agents; cardiovascular disorders; antilipemic agents | CETP, CES1, PON1 | CETP 1/4885MDM4 4274/4885TP53 4544/4885 |
| US-12371748-B2 | Genetic markers for predicting responsiveness to therapy with HDL-raising or HDL mimicking agent | CETP, HDLBP, APOB | CETP 1/4885MDM4 2865/4885TP53 2724/4885 |
| US-20040242683-A1 | Method for increasing the bioavailability of the active form of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl] amino)phenyl] 2-methylpropanethioate | SLC7A1, SLC10A2, SLC19A2 | CETP 99/4885MDM4 3359/4885TP53 4481/4885 |
| US-20050020668-A1 | Combination comprising S-[2-([[1-(2-ethylbutyl)cyclohexyl] carbonyl]amino)phenyl] 2-methylpropanethioate and an HMG CoA reductase inhibitor | HMGCR, COASY, PCSK9 | CETP 8/4885MDM4 4120/4885TP53 4615/4885 |
| US-20040225018-A1 | administering S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl] 2-methylpropanethioate and a water-insoluble concentration-enhancing additive crospovidone, for treating or preventing a cardiovascular disorder in a mammal | CETP, MTTP, PCTP | CETP 1/4885MDM4 4453/4885TP53 3398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.